You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Multi-path DCS as a novel non-invasive treatment for amyotrophic lateral sclerosis
SBC: PATHMAKER MOBILITY CORP. Topic: 109PROJECT SUMMARY / ABSTRACT Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the spinal cord and brain. ALS causes muscle weakness and paralysis and eventually death. According to the ALS Association, every 90 minutes there is a new diagnosis of ALS, as well as an associated death. Nearly 5,000 people are diagnosed with ALS each year and a ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery
SBC: MERCATOR MEDSYSTEMS, INC. Topic: NHLBIPROJECT SUMMARY Post-thrombotic syndrome (PTS) is a chronic debilitating condition characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. It occurs within 2 years of deep vein thrombosis (DVT) treatment in 50-60% of patients with iliofemoral thrombosis and in 30-50% of all DVT patients regardless of thrombosis location (1). Even with pharmacolo ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A novel approach to Mesenchymal Stem Cell Transduction
SBC: OSSIUM HEALTH INC Topic: NHLBIPROJECT SUMMARY Mesenchymal stem cells (MSC) are in clinical development for cardiovascular, neurologic, orthopedic, and other indications. Ossium is developing a novel source of MSC from vertebral bodies (vbMSC). Genetic modification of vbMSC using lentiviral vector (LV) has the potential to improve the therapeutic potential. Understanding how genetic modification might alter the vbMSC phenotype ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Xenon gas treatment to modulate microglia in neurodegenerative diseases
SBC: General Biophysics LLC Topic: NIAAdministrative Supplement Application PA-20-272 Xenon gas treatment to modulate microglia in neurodegenerative diseases (R41AG073059) ABSTRACT ABSTRACT FROM ORIGINAL APPLICATION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Treat Parkinson’s Disease
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: 107PROJECT SUMMARY The goal of the proposed project is to evaluate the potential of HBI-002, a novel oral formulation of carbon monoxide (CO), as a neuroprotective agent in Parkinson’s disease (PD). A growing body of research suggests that low doses of CO - and the heme oxygenase (HO) enzymes that generate endogenous CO - protect against neuronal cell loss in PD, and epidemiologic studies have asso ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A Smart Assistant for MRI Technologists
SBC: Biopac Systems, Inc. Topic: NIBIBAbstract Magnetic resonance imaging (MRI) is critically important for pediatric care and the unusable data caused by patient motion has been estimated to cost $1.4B per year in the United States alone. Currently, a radiologist assesses if the images are satisfactory or not, but an MRI technologist does the imaging, and coordination of communication between the two is costly and slow. We propose to ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy
SBC: MICROCURES INC Topic: 300Radical prostatectomy (RP) is a commonly used treatment option for localized prostate cancer, which carries a high risk for development of erectile dysfunction (ED) because of cavernous nerve (CN) injury. Even newer, nerve-sparing, robotic procedures do not convincingly improve erectile function (EF) outcomes after RP. In addition, ED resulting from RP is often refractory to treatment by orally ad ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease
SBC: WELLSIM BIOMEDICAL TECHNOLOGIES INC Topic: NIAPROJECT SUMMARY / ABSTRACT Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extra ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics
SBC: BUTO CORPORATION Topic: NIAAbstract. Alzheimer’s disease (AD) affects more than 5M Americans today, and is the most common cause of dementia in adults. While current medications slightly delay symptoms, no medications exist to cure or stop disease progression. A current focus at NIA is to identify novel drug targets, that address resilience to AD; also, there is an increasing perspective at NIA that Multi-target therapy m ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Engineering a long-acting relaxin agonist to treat liver fibrosis
SBC: ZEBRA BIOLOGICS INC Topic: 300Project Summary/AbstractRelaxin is a heterodimeric 53 amino acid peptide hormone that induces cardiovascular compliance and reproductive tissue remodeling during pregnancy and parturition. In addition to reproductive organs, the relaxin receptor, RXFP1, is also expressed in the liver, heart, lung, kidney, bone and skin. This broad tissue localization has led to the recognition that relaxin is a pl ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health